🇰🇷 🇨🇭 BREAKING: Samsung Biologics to acquire Switzerland’s PolyPeptide Group in $1.8 billion all-cash deal. The acquisition is the largest biopharmaceutical M&A deal in the country’s history. Peptide therapeutics are medicines made from short chains of amino acids, including some GLP-1 obesity and diabetes drugs that mimic a natural hormone to reduce appetite and regulate blood sugar.
AlgoTrader 